StockWatch: Novartis Loses More than Market Value After Phase III Failure
Novartis (SIX Swiss: NOVN and NYSE: NVS) lost more than just the roughly $30 billion in market capitalization (share price times the number of outstanding shares) that dried up this past week when the company said its neuromuscular candidate delpacibart …